Heart Failure With Preserved Ejection Fraction Clinical Trials 2023

What are the top hospitals conducting heart failure with preserved ejection fraction research?

When it comes to advancing the understanding and treatment of heart failure with preserved ejection fraction, several top hospitals are leading the way. In Boston, Massachusetts General Hospital takes center stage with eight active clinical trials dedicated to this condition. While they have only recorded two trials in total since their first investigation in 2020; their commitment is evident. On the other side of the country, the Medical University of South carolina in Charleston has been making significant contributions as well. With seven ongoing trials and a single completed trial since initiating research on heart failure with preserved ejection fraction in 2017, this institution's dedication shines through.

Meanwhile, at Yale University in New Haven, researchers are currently conducting six active clinical trials for heart failure with preserved ejection fraction - an impressive feat considering they had no previous documented investigations on this specific condition. This demonstrates their commitment to exploring new avenues and improving patient outcomes.

In Durham, North carolina, Duke University Medical Center boasts five ongoing clinical trials focused on heart failure with preserved ejection fraction. Having commenced their pioneering work back in 2008 and accumulating two all-time trials thus far showcases their longstanding dedication to tackling this complex condition.

Lastly but certainly not least is Northwestern University located at Chicago which despite its relatively smaller-scale approach toward such cases having just four current researches going on also holds prideful experience by contributing comprehensive knowledge from previously conducted experiments amounting up-to-date discoveries encompassing downheartedness attaining preservation of useful cardiac output only initiated about a year ago i.e.,2020

These esteemed institutions dedicate substantial efforts towards unlocking breakthroughs that can greatly impact patients living with heart failure with preserved ejection fraction—a condition known for its challenges due to limited treatment options available currently.As these hospitals continue tirelessly working towards advancements within cardiovascular health field; brighter future awaits countless individuals grappling against grave nature conditions

Which are the best cities for heart failure with preserved ejection fraction clinical trials?

When it comes to clinical trials focused on heart failure with preserved ejection fraction, several cities have emerged as leading centers of research. Philadelphia, Pennsylvania leads the pack with 21 active trials, investigating treatments such as Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System and mavacamten. Boston, Massachusetts closely follows with 20 ongoing studies exploring interventions like AccuCinch Ventricular Restoration System and Atorvastatin. New york City also plays a significant role in this field with 14 active trials examining therapies such as Beta Blocker BABA Sequence and Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System. These three cities are at the forefront of clinical research for heart failure with preserved ejection fraction, offering promising opportunities for patients seeking innovative treatment options.

Which are the top treatments for heart failure with preserved ejection fraction being explored in clinical trials?

Heart failure with preserved ejection fraction (HFpEF) clinical trials are uncovering potential breakthroughs in treatment. Atorvastatin, a well-established medication, is currently being explored in two active HFpEF trials. Since its first listing in 2005, it has been involved in two all-time HFpEF trials. Another promising contender is dapagliflozin—a newcomer to the field—with two ongoing HFpEF trials and one previous trial since its introduction last year. These investigations offer hope for improved management of HFpEF and bring us closer to effective treatments for this challenging condition.

What are the most recent clinical trials for heart failure with preserved ejection fraction?

Recent clinical trials have provided promising insights into the management and treatment of heart failure with preserved ejection fraction. One such study focused on an intervention group, evaluating its effectiveness in addressing this condition across Phase 1 and Phase 2 trials. Another trial explored the benefits of an on-off sequence approach for heart failure patients, aiming to optimize treatment outcomes. Additionally, JTT-861 Dose 1 has shown potential as a therapeutic option in Phase 2 trials. The use of Furoscix has also been investigated as a possible treatment for heart failure with preserved ejection fraction. Lastly, a Phase 4 trial examined the impact of Medication & Education-First strategies on managing this specific type of heart failure. These recent clinical trials offer hope for improved patient outcomes and contribute valuable knowledge to the field's understanding of heart failure with preserved ejection fraction.

What heart failure with preserved ejection fraction clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the research of heart failure with preserved ejection fraction (HFpEF). These studies focus on examining potential treatments for this condition. The National Institutes of Health (NIH) recently concluded a trial investigating the effectiveness of sacubitril/valsartan, a combination therapy targeting HFpEF. Another noteworthy trial sponsored by Novartis Pharmaceuticals explored the use of spironolactone as a treatment option. Both trials provide valuable insights into potential therapies and offer hope for patients suffering from HFpEF.